EN DE
Watch Medicskin Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medicskin Holdings Ltd (8307) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Medicskin Holdings Ltd stock HK$0.05, price HK$0.16, that is 67.7% below the price, quality 61 out of 100. Rating: strongly overvalued. Calculated from audited financials with 20 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN KYG595641070

MH Medicskin Holdings Ltd logo Thin data Nov 15, 2026

Medicskin Holdings Ltd

8307 · HK

Far too expensive (fair value 68% below the price) and falling price, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Quality 61/100 
Generates free cash flow 
Mixed Growth (revenue 5y +2.8 %/yr in HKD) 
Thin margins · 1.9% net margin (TTM) 
Mixed vs. peers (5/11) 
Profit last quarter 78% below a year ago. 
Fair value HK$0.0500 · Strongly overvalued 
Falling price (downtrend) 
Narrow moat 36/100 · thin data
Thin data 
Watch Medicskin Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.3500 HK$0.0920 Fair Value HK$0.0500 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range HK$0.0920 – HK$0.3500 · fair‑value band HK$0.0400 – HK$0.0600 · the HK$0.1550 price screens above the HK$0.0500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Medicskin Holdings in your weekly email

Every Wednesday you see whether Medicskin Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medicskin Holdings Limited, an investment holding company, provides medical skin care services in Hong Kong.

Show moreShow less

The company operates Medicskin centers, which provides various medical skin care services for the treatment of skin diseases and problems, such as acne, pigmentation, rosacea, dermatitis, eczema, and warts, as well as improvement of appearance through inter alia, skin rejuvenation, facial sculpturing, and body contouring treatments; and treatment of acne scars and enlarged pores, removal of undesirable naevi, and hair removal.

It provides medical consultancy services. In addition, the company engages in the sale of skincare products.

Further, it provides health management services; prescription and dispensing services of pharmaceutical products, medicines, and skincare products; and non-invasive/minimally invasive treatment services. Medicskin Holdings Limited was founded in 2000 and is headquartered in Sheung Wan, Hong Kong.

Medicskin Holdings Limited is a subsidiary of Topline Worldwide Limited.

Stock analysis

Medicskin Holdings Ltd (8307) currently trades at HK$0.1550, while our model-based Fair Value estimate is HK$0.0500, 68% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of HK$0.1550 per share, and 6 of the 20 models we run sit above the HK$0.1550 price.

Bear case: the Asset-Based group reads lowest at HK$0.0100, and 14 of the 20 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.0400 (bear) to HK$0.0600 (bull), the price of HK$0.1550 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Medicskin Holdings Ltd reported revenue of HK$47.9M in FY2026 versus HK$49.1M in FY2022, a compound −0.7%/yr. Reported net income was HK$936K in FY2026, compounding −30.1%/yr from FY2022.

Key figures

Market cap HK$61.5M (≈ $7.8M) Micro · P/S ratio 1.28 · Net margin 1.9% · Return on equity 19.9% · Return on assets (EBIT) 4.1% (5-year average) · Operating margin 1.4% · Revenue (TTM) HK$48.2M · Revenue growth (YoY) +8.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 52% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −68%, 8307 screens richer than that median.

Fair Value models

Bear HK$0.0400 Fair Value HK$0.0500 Bull HK$0.0600
Price HK$0.1550 · Downside -67.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$0.1500 HK$0.1800 HK$0.2500 80
Growth DCF HK$0.1500 HK$0.1900 HK$0.2400 77
Owner Earnings HK$0.1600 HK$0.2000 HK$0.2700 75
All 20 models by family
DCF Models
FCF DCF HK$0.1500 HK$0.1800 HK$0.2500 80
Owner Earnings HK$0.1600 HK$0.2000 HK$0.2700 75
5Y Revenue Exit HK$0.0800 HK$0.0900 HK$0.1000 71
5Y EBITDA Exit HK$0.1800 HK$0.2500 HK$0.3500 73
5Y P/E Exit HK$0.1000 HK$0.1100 HK$0.1400 69
10Y Revenue Exit HK$0.1100 HK$0.1100 HK$0.1200 66
10Y EBITDA Exit HK$0.1600 HK$0.2100 HK$0.2600 67
10Y P/E Exit HK$0.1200 HK$0.1300 HK$0.1400 63
Earnings-Based
Graham-Dodd HK$0.0200 HK$0.0200 HK$0.0200 67
EPV HK$0.0400 HK$0.0400 HK$0.0400 70
Multiples
P/E Multiple HK$0.0400 HK$0.0500 HK$0.0600 63
P/S Multiple HK$0.0300 HK$0.0400 HK$0.0500 58
P/B Multiple HK$0.0400 HK$0.0600 HK$0.0700 55
EV/EBITDA HK$0.1800 HK$0.2500 HK$0.3100 64
Asset-Based
NCAV (Graham) HK$0.0100 HK$0.0100 HK$0.0100 53
Growth DCF
Growth DCF HK$0.1500 HK$0.1900 HK$0.2400 77
Rev-Margin DCF HK$0.0800 HK$0.0900 HK$0.1000 71
Economic Profit
Residual Income HK$0.0100 HK$0.0200 HK$0.0200 71
ROIC Compounder HK$0.0400 HK$0.0400 HK$0.0400 70
Growth Earnings
Growth-Adj P/E HK$0.0300 HK$0.0400 HK$0.0500 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 61/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 49
How much profit the company makes from its sales and capital
Quality Growth 61
Are margins and returns getting better?
Cashflow 67
Do the profits arrive as real cash?
Financial strength 22
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 42
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 32
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Start year 2021 (pandemic). Over 10 years: −2.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−17.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17.2% vs −10.7%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−6% → 1%
Pace: the 5-year rate starts in 2021 (pandemic)
⚠ Revenue per share shrinking 4.4%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about −5.7% a year for the price.

8307 screens overvalued: fair value 68% below the price. Compare with HCA Healthcare, Inc →

Compare Medicskin Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 61 · Above median
Fair Value upside −67.7% · Bottom 25%
Profitability
Return on equity (12 months) 19.9% · Top 25%
Return on assets 1.8% · Below median
Net margin (12 months) 1.9% · Below median
Operating margin (12 months) 1.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 8.0% · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 11.77× · Priciest 25%
P/S (12 months) 1.28× · Cheaper than median
Price / free cash flow (fiscal year) 13.5× · Cheaper than median
EV/EBITDA 20.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)40 · sector 31
PAST (return on equity)79 · sector 31
HEALTH (low debt)0 · sector 90
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs 8307
DaVita Inc DVA $174.56 $218.90 +25% vs 8307
Aier Eye Hospital Group 300015 ¥8.84 ¥10.88 +23% vs 8307
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs 8307
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs 8307
The Ensign Group ENSG $188.41 $140.09 −26% vs 8307
Encompass Health Corporation EHC $140.99 $94.81 −33% vs 8307
Fresenius SE FRE €53.62 €34.77 −35% vs 8307
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,526 ₹5,234 −39% vs 8307
Dr. Sulaiman Al Habib Medical Services Group 4013 212.10 SAR 109.45 SAR −48% vs 8307

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medicskin Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medicskin Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8307

Frequently asked questions

Is Medicskin Holdings Ltd (8307) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of HK$0.0500 versus a price of HK$0.1550, about 68% lower (overvalued).
What is the fair value of 8307?
Our model-based fair value for Medicskin Holdings Ltd is HK$0.0500 (as of Nov 15, 2026), built from audited fundamentals. The current price: HK$0.1550.
What is the quality score of 8307?
Medicskin Holdings Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medicskin Holdings Ltd (8307)?
Our model-based price target is the fair value of HK$0.0500 (as of Nov 15, 2026) from 20 valuation models. Cautious scenario HK$0.0400, optimistic scenario HK$0.0600. It is a calculation from audited fundamentals, not an analyst target.
What is the Medicskin Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$0.0500, about 68% lower versus a price of HK$0.1550 (overvalued). Cautious scenario HK$0.0400, optimistic scenario HK$0.0600. The calculation is refreshed regularly with new filings.
What is the revenue of Medicskin Holdings Ltd (8307)?
Medicskin Holdings Ltd reported trailing-twelve-month revenue of about HK$48.2M (latest available figure, as of Nov 15, 2026).
What growth is priced into Medicskin Holdings Ltd (8307)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Medicskin Holdings Ltd shrinks by 3.7 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 2.8 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of 8307 use?
Our models discount Medicskin Holdings Ltd at 10.3 %: a base by market capitalisation (nano), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medicskin Holdings Ltd that is -3.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Medicskin Holdings Ltd (8307) delivered so far?
Over the past 5 years revenue at Medicskin Holdings Ltd grew 2.8 % a year. The price currently implies free-cash-flow growth of -3.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medicskin Holdings Ltd (8307) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Medicskin Holdings Ltd (-3.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medicskin Holdings Ltd (8307)?
The free-cash-flow yield on the price is 7.39 %: that much free cash flow Medicskin Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medicskin Holdings Ltd (8307)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medicskin Holdings Ltd it is HK$0.0500 per share (as of Nov 15, 2026), against a price of HK$0.1550. It is the blended result of 20 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Medicskin Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 8307 trades above its calculated fair value: price HK$0.1550, fair value HK$0.0500, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8307?
No. The price is what the market pays today (HK$0.1550); the fair value is what the company's own numbers justify (HK$0.0500). For Medicskin Holdings Ltd the two are HK$0.1050 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medicskin Holdings Ltd worth?
The market values Medicskin Holdings Ltd at about HK$61.5M (market capitalisation, as of Nov 15, 2026). Per share that is HK$0.1550; our models calculate a fair value of HK$0.0500 per share.
What do the bullish and bearish scenarios say about 8307?
Our models span a range for Medicskin Holdings Ltd: cautious scenario HK$0.0400, base HK$0.0500, optimistic HK$0.0600 per share (as of Nov 15, 2026, price HK$0.1550). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medicskin Holdings Ltd (8307)?
Balance-sheet figures for Medicskin Holdings Ltd (as of Nov 15, 2026): return on equity 19.9%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 8307 from its 52-week high?
Medicskin Holdings Ltd trades at HK$0.1550, about 23% below its 52-week high of HK$0.2000 and 52% above the low of HK$0.1020 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0500 is for.
Which stocks are comparable to Medicskin Holdings Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medicskin Holdings Ltd stock attractive at the current price?
The data as of Nov 15, 2026: price HK$0.1550, calculated fair value HK$0.0500 (−68%), Quality Score 61/100, from 20 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8307 calculated?
We run Medicskin Holdings Ltd through 20 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$0.0500 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Medicskin Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medicskin Holdings Ltd (8307)?
The closing price on Nov 13, 2026 was HK$0.1550. Our model-based fair value is HK$0.0500, about 68% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medicskin Holdings Ltd right now?
The price sits above even our optimistic bull case (HK$0.0600). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Medicskin Holdings Ltd

How large is the market capitalisation of Medicskin Holdings Ltd (8307)?
The market capitalisation of Medicskin Holdings Ltd is HK$61.5M (≈ $7.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medicskin Holdings Ltd (8307)?
The price-to-sales ratio of Medicskin Holdings Ltd is 1.28 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Medicskin Holdings Ltd (8307)?
The net margin of Medicskin Holdings Ltd is 1.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medicskin Holdings Ltd (8307)?
The return on equity (ROE) of Medicskin Holdings Ltd is 19.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medicskin Holdings Ltd (8307)?
On an EBIT basis the return on assets of Medicskin Holdings Ltd is 4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medicskin Holdings Ltd (8307)?
The operating margin of Medicskin Holdings Ltd is 1.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medicskin Holdings Ltd (8307)?
Revenue at Medicskin Holdings Ltd is growing 8.0% versus a year earlier (3y avg +1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medicskin Holdings Ltd (8307)?
Earnings per share at Medicskin Holdings Ltd are down 77.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medicskin Holdings Ltd (8307) carry?
The net debt of Medicskin Holdings Ltd is HK$6.0M (fiscal year 2026, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medicskin Holdings Ltd in the live analysis

One click puts Medicskin Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.